Download PDF

1. Company Snapshot

1.a. Company Description

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders.The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia.It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex.


The company operates in approximately 40 countries worldwide.Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd.The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Show Full description

1.b. Last Insights on INDV

Have nothing to say about that one ...

1.c. Company Highlights

2. Indivior's 2025 Earnings: A Strong Finish with SUBLOCADE Leading the Way

Indivior Pharmaceuticals Inc reported a strong financial performance for the fourth quarter and full year 2025, driven by the continued growth of its flagship product, SUBLOCADE. The company achieved record net revenue of $856 million for SUBLOCADE, representing a 13% increase versus 2024, and total net revenue of $1.24 billion, a 4% increase compared to the prior year. The company's adjusted EBITDA grew 20% year-over-year to $428 million in 2025, demonstrating its ability to expand margins. The actual EPS came out at $0.2943, beating estimates of $0.1807.

Publication Date: Mar -08

📋 Highlights
  • Record SUBLOCADE Revenue:: Generated $856 million in net revenue, a 13% increase YoY, driving total net revenue to $1.24 billion (+4%).
  • 2026 Financial Guidance Reaffirmed:: Total revenue $1.125–$1.195 billion; SUBLOCADE revenue $905–$945 million; adjusted EBITDA $535–$575 million (+30% YoY, 13pp margin expansion).
  • Capital Deployment Strategy:: $400 million share repurchase program authorized, prioritizing debt management, buybacks, and strategic M&A with assets having >$200 million peak sales potential.
  • LAI Market Expansion:: SUBLOCADE LAI penetration at ~9%, aiming to grow via consumer education and expanding new patient share; LAI category grew 18% in Q4 2025.
  • Cash Flow Strength:: Ended 2025 with $222 million in cash; expects >$300 million in 2026 operating cash flow, supporting SG&A stability and debt reduction.

Guidance and Outlook

The company provided guidance for 2026, expecting total net revenue in the range of $1.125 billion-$1.195 billion and total SUBLOCADE net revenue in the range of $905 million-$945 million. The company expects to deliver SUBLOCADE dispense unit growth in the mid-teens in 2026 and SUBLOCADE net revenue growth of 8% at the midpoint of its guidance range. Analysts estimate next year's revenue growth at 7.2%, which is slightly below the company's guidance.

Capital Deployment and Share Repurchase

Indivior's board has authorized a new $400 million share repurchase program, demonstrating the company's commitment to returning value to shareholders. The company's capital deployment priorities include managing debt, opportunistic share repurchases, and evaluating potential business development opportunities. The company's gross cash and investments stood at $222 million at the end of 2025, and it expects to generate over $300 million in cash flow from operations in 2026.

Valuation and Metrics

Using the current valuation metrics, Indivior's P/E Ratio stands at 19.21, and its EV/EBITDA ratio is 13.89. The company's ROE is -98.94%, and ROIC is 80.92%, indicating a strong operating performance. The Net Debt / EBITDA ratio is 0.52, suggesting a manageable debt burden. These metrics suggest that the market is pricing in a certain level of growth and profitability for the company.

Growth Opportunities and Challenges

Indivior is focused on growing its LAI penetration, which currently stands at around 9%, with a goal to increase it. The company's market share has stabilized in the mid-70%, with a focus on new patient share, which has been strong. The company sees opportunities for growth in the criminal justice system and is evaluating business development opportunities in therapeutic areas outside of opioid use disorder. However, the company's international revenue, excluding the US, is expected to be relatively flat year-over-year.

3. NewsRoom

Card image cap

Indivior to Participate in Upcoming Investor Events

Aug -20

Source:

Card image cap

The Street Loves This ‘Strong Buy’ Pharma Stock

Aug -08

Source:

Card image cap

All You Need to Know About Indivior (INDV) Rating Upgrade to Strong Buy

Aug -05

Source:

Card image cap

Best Momentum Stock to Buy for August 5th

Aug -05

Source: zacks.com

Card image cap

Indivior Plc (INDV) Jumps 22.8% on Impressive Earnings, Outlook

Aug -03

Source:

Card image cap

Indivior (INDV) Extends Jump on 3rd Day with 16% Gain

Aug -01

Source:

Card image cap

Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates

Jul -31

Source:

Card image cap

Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance

Jul -31

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.00%)

6. Segments

Buprenorphine-based Prescription Drugs

Expected Growth: 11%

Indivior PLC's Buprenorphine-based prescription drugs segment growth is driven by increasing opioid addiction awareness, favorable government policies, and rising demand for medication-assisted treatment. Additionally, the company's strong brand presence, expanding distribution channels, and ongoing research and development efforts contribute to the 11% growth.

7. Detailed Products

Suboxone Film

A prescription medication used to treat opioid dependence in adults and adolescents aged 16 and older.

Suboxone Tablet

A prescription medication used to treat opioid dependence in adults.

Subutex

A prescription medication used to treat opioid dependence in adults.

Perseris

A once-monthly injectable medication used to treat schizophrenia in adults.

8. Indivior PLC's Porter Forces

Forces Ranking

Threat Of Substitutes

Indivior PLC faces moderate threat from substitutes as there are alternative treatment options available for opioid addiction, such as methadone and buprenorphine. However, Sublocade, Indivior's flagship product, has a unique selling proposition as a once-monthly injectable treatment, which differentiates it from other options.

Bargaining Power Of Customers

Indivior PLC's customers, primarily healthcare providers and patients, have limited bargaining power due to the company's strong brand presence and limited availability of alternative treatment options for opioid addiction.

Bargaining Power Of Suppliers

Indivior PLC's suppliers, primarily pharmaceutical ingredient manufacturers, have moderate bargaining power due to the company's dependence on a limited number of suppliers for its products. However, the company's strong relationships with its suppliers and the complexity of the manufacturing process mitigate the bargaining power of suppliers.

Threat Of New Entrants

The threat of new entrants in the opioid addiction treatment market is low due to the high barriers to entry, including the need for significant investment in research and development, regulatory approvals, and manufacturing capabilities.

Intensity Of Rivalry

The intensity of rivalry in the opioid addiction treatment market is high due to the presence of established players, such as Alkermes and Titan Pharmaceuticals, and the increasing competition from new entrants. Indivior PLC faces intense competition in terms of pricing, product offerings, and marketing efforts.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 17.69%
Debt Cost 4.97%
Equity Weight 82.31%
Equity Cost 4.97%
WACC 4.97%
Leverage 21.49%

11. Quality Control: Indivior PLC passed 1 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Indivior

A-Score: 5.0/10

Value: 4.2

Growth: 2.8

Quality: 7.4

Yield: 0.0

Momentum: 9.5

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Eagle Pharma

A-Score: 4.5/10

Value: 10.0

Growth: 1.8

Quality: 8.3

Yield: 0.0

Momentum: 7.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
TherapeuticsMD

A-Score: 4.3/10

Value: 6.8

Growth: 4.8

Quality: 4.8

Yield: 0.0

Momentum: 8.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Organogenesis Holdings

A-Score: 4.1/10

Value: 5.9

Growth: 3.9

Quality: 5.7

Yield: 0.0

Momentum: 8.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Assertio

A-Score: 3.5/10

Value: 9.4

Growth: 2.7

Quality: 4.5

Yield: 0.0

Momentum: 1.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Alpha Teknova

A-Score: 2.0/10

Value: 4.9

Growth: 1.3

Quality: 3.6

Yield: 0.0

Momentum: 0.5

Volatility: 1.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

12.38$

Current Price

12.38$

Potential

-0.00%

Expected Cash-Flows